Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge
Awards up to $13.1 million across three phases to US-based teams developing novel technologies that target RNA to treat human disease.
About
The challenge runs in three phases. Phase I (closed) awarded up to $20,000 each to as many as 25 planning-stage winners. Phase II asks for a prototype technology and a use case, split into a Stage I interim milestone (up to $120,000 each, up to 25 winners, submissions Dec 1, 2026 to Feb 1, 2027) and a Stage II final submission open only to Stage I winners (up to $320,000 each, up to 15 winners). P…
BiotechMedtech
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.